Adverse effects of amoxicillin may be potentially under-reported
the ONA take:
Amoxicillin is a widely used antibiotic in the penicillin group of drugs. It is used to treat bacterial infections in patients with cancer, and may be used as prophylaxis in some patients. In a systematic review, researchers conducted a review of controlled trials to assess potential harms related to amoxicillin use.
The review included a total of 45 trials, featuring a total of 10,519 participants. The researchers found that almost twice as many patients receiving amoxicillin had diarrhea compared with patients receiving placebo, and diarrhea was more than three times more likely among participants receiving amoxicillin-clavulanate. An association between candidiasis and amoxicillin-clavulanic acid use was also observed.
However, the authors acknowledge a limitation to their study. All the trials measured efficacy rather than harm as their primary outcome, and only 25 of the study included information on harms. Therefore, the number of harms reported was lower than expected, which contributed to a conclusion that harms may be under-reported in clinical trials. In a related commentary, clinicians are advised to be wary of the lack of information on potential adverse effects from amoxicillin.
Researchers conducted a review of controlled trials to assess potential harms related to amoxicillin use.
- FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Efficacy of Octreotide LAR, Lanreotide in Management of Carcinoid Tumors
- Multivitamin Use May Reduce Risk of Chemo-Induced Neuropathy
- Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
- Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC
- Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer
- Cannabis Reduces Response Rate to Immunotherapy for Cancer
- Perioperative Blockade of Pathways May Improve Outcomes in Breast Cancer
- Zika Virus Preferentially Targets Glioblastoma Stem Cells
- Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications
- Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium
- Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
- Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting
- Severe Mental Illness May Worsen Breast Cancer Survival Outcomes
- Imaging Management of Breast Density, a Controversial Risk Factor for Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|